DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1765)

Peripheral Arterial Disease | Landscape and Forecast | Disease Landscape and Forecast

Peripheral Arterial Disease | Landscape and Forecast | Disease Landscape and Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming November 2018

Market Outlook

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities and is a major cause of morbidity and mortality in developed countries. PAD is considered a major marker for systemic ischemic events such as stroke and myocardial infarction (MI). With asymptomatic patients making up a large percentage of the total PAD population, PAD is largely underdiagnosed, under-recognized, and undertreated. However, there is a growing recognition that optimal management of PAD requires aggressive secondary prevention measures. Few drugs have been developed specifically for PAD and the choice of therapies have changed little in recent years, but novel several therapies are currently in development. Increasing diagnosis and treatment rates, combined with substantial unmet need, make PAD a high-growth opportunity.

Questions answered

  • Generic competition dominates the PAD market, with sales of branded formulations severely limited. What impact will the launch of novel branded drugs have on the PAD market? Which patients will these therapies likely be used in?
  • Research and development of novel PAD therapies has spanned a variety of mechanisms of action, and routes of administration. However, few therapies have demonstrated clinical benefit in PAD patients, thus failing to reach the market with a PAD indication. How active is current drug development? What are thought leader’s opinions on the prospects of therapies still in development?
  • There is a substantial treatment gap in PAD patients, with a considerable percentage of patients remaining undiagnosed and untreated. How do thought leader think this treatment gap can be reduced? What effect will the introduction of new therapies have?

Product description

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 20 country-specific interviews with PAD experts.

Epidemiology: Prevalence of PAD by total population, and severity; Acute PAD-associated events; Diagnosis status.

Population segments in market forecast: Asymptomatic, intermittent claudication, critical limb ischemia.

Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.

Market forecast features: We forecast drug sales for asymptomatic, intermittent claudication, and critical limb ischemia patients segments through 2027.

Table of contents

  • Disease Landscape and Forecast
    • Coming Soon
      • Coming Soon

Coming soon

Already a Client? Log in to access this report.

  • Pub Date: December 2018
  • Author(s): David Rees, Ph.D
  • David Rees, , is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate from the University of Bath.

Purchase Report

Recent reports:
You may also be interested in: